LGC and AKOS combine to offer expanded drug development services
LGC has formed a strategic alliance with AKOS, the UK-based specialist drug development and regulatory affairs consultancy company, that will enable both parties to expand the range of services they offer to drug discovery companies. AKOS specialises in leading clients from drug discovery through the development process, and has a strong track record of enabling organisations to achieve their strategic aims, including onward sale or licensing, through to marketing authorisation. LGC offers a wide range of analytical services and instrumentation that are applied across the drug development cycle from early phase discovery through to clinical trial. Through this alliance clients will benefit from the best in advice and services that will enhance the development and valuation of new products.
Other news from the department business & finance
These products might interest you
Good Weighing Practice by Mettler-Toledo
Your Concrete Weighing Quality Assurance Plan
GWP Verification service
Milli-Q® Services / MyMilli-Q™ by Merck
Services & Support for Water Purification Systems
Quality Care, Delivered. In Person & Online
Most read news
More news from our other portals
Last viewed contents
European_Gemological_Laboratory_(USA)
BASF raises prices for Neopentylglycol and Trimethylolpropane
Better thermal conductivity by adjusting the arrangement of atoms
Günter_Wirths
Eco-friendly micro-supercapacitors using fallen leaves - Femtosecond micro-supercapacitors on a single leaf could easily be applied to wearable electronics, smart houses, and IoTs
New metamaterial paves way for terahertz technologies
Early Screening, Innovative Solutions to Underline Importance of ADME/Tox Technologies in Successful Drug Development - Considerable Time, Cost Savings to Accrue from Advanced ADME/Tox Technologies
Wacker Boosts Supply for Surface Coating Resins
Fueling the future - Scientists promote new method of algal hydrogen production
